SPX4,158.24+100.40 2.47%
DIA332.07+5.62 1.72%
IXIC12,131.13+390.48 3.33%

BRIEF-Abbvie Says RINVOQ Approved By U.S. FDA As An Oral Treatment For Adults With Active Ankylosing Spondylitis

reuters.com · 04/29/2022 14:52
BRIEF-Abbvie Says RINVOQ Approved By U.S. FDA As An Oral Treatment For Adults With Active Ankylosing Spondylitis

- Abbvie Inc ABBV:

  • ABBVIE INC - RINVOQ® (UPADACITINIB) APPROVED BY U.S. FDA AS AN ORAL TREATMENT FOR ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS

  • ABBVIE INC - RINVOQ DEMONSTRATED SIGNIFICANT IMPROVEMENT IN SIGNS AND SYMPTOMS OF AS AT WEEK 14

  • ABBVIE - ACROSS 2 TRIALS, RINVOQ DELIVERED RAPID, MEANINGFUL DISEASE CONTROL WITH NEARLY HALF OF AS PATIENTS ACHIEVING ASAS40 AT WEEK 14 VERSUS PLACEBO

Source text for Eikon: ID:nPn76zxQDa

Further company coverage: ABBV


((Reuters.Briefs@thomsonreuters.com;))